(BIOA) (BIOA) News Today → Move Your Money Before May 1 (From Stansberry Research) (Ad) Free BIOA Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Share Share HeadlinesStock Analysis All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineLeqembi® revenue totaled JPY 2.83 billion in the first quarter 2024finance.yahoo.com - April 24 at 8:36 AMBioArctic And Eisai Collaborate On Evaluating BAN2802 For Alzheimer's Diseasemarkets.businessinsider.com - April 21 at 12:24 AMThe Nomination Committee's proposal for the election of Board members and Chairperson of the Board in BioArctic ABfinanznachrichten.de - April 16 at 10:11 AMCamurus AB CAMXmorningstar.com - April 12 at 4:14 PMBioArctic's focus on Sustainable Innovation qualifies company for new ESG Responsibility Index at Nasdaq Stockholmfinance.yahoo.com - April 10 at 7:48 AMB Jun 2024 50.000 callfinance.yahoo.com - April 6 at 11:19 PMB Sep 2024 40.000 putfinance.yahoo.com - April 6 at 2:02 AMB Sep 2024 30.000 putfinance.yahoo.com - April 6 at 2:02 AMSubmission of Leqembi® (lecanemab-irmb) sBLA for IV maintenance dosing for the treatment of early Alzheimer's disease to the U.S. FDA completedfinance.yahoo.com - April 1 at 2:15 AMLecanemab deliberations at the CHMP regarding the Marketing Authorisation Application in the EU have been rescheduled due to procedural reasonsfinance.yahoo.com - March 22 at 8:12 AMB Apr 2024 30.000 putfinance.yahoo.com - March 16 at 8:27 AMB Apr 2024 40.000 callfinance.yahoo.com - March 16 at 8:27 AMB Apr 2024 45.000 callfinance.yahoo.com - March 16 at 1:52 AMBioArctic: New data on lecanemab presented at the 2024 AD/PD™ congressfinance.yahoo.com - March 11 at 9:34 AMBioArctic's partner Eisai presents updated sales simulation for Leqembi® at its annual press conferencefinance.yahoo.com - March 7 at 7:28 AMBioArctic: Latest data on lecanemab to be presented at the 2024 AD/PD congressfinanznachrichten.de - February 29 at 9:08 AMBioArctic: Latest data on lecanemab to be presented at the 2024 AD/PD™ congressfinance.yahoo.com - February 29 at 9:08 AMBioiasis AD BIOAmorningstar.com - February 17 at 3:25 PMBioArctic: Sales of Leqembi® totaled 1.1 billion yen in the fourth quarter 2023finanznachrichten.de - February 6 at 2:16 AMSales of Leqembi® totaled 1.1 billion yen in the fourth quarter 2023finance.yahoo.com - February 6 at 2:16 AMThe European Medicines Agency's Scientific Advisory Group (SAG) to discuss the Marketing Authorisation Application for lecanemab: BioArcticfinance.yahoo.com - January 11 at 9:08 AMBioArctic: Leqembi® approved for the treatment of Alzheimer's disease in Chinafinanznachrichten.de - January 9 at 7:46 AMLeqembi® approved for the treatment of Alzheimer's disease in Chinafinance.yahoo.com - January 9 at 7:46 AMLEQEMBI® to be launched in Japan for Alzheimer's disease on December 20finance.yahoo.com - December 13 at 10:01 AMBioArctic: LEQEMBI® to be launched in Japan for Alzheimer's disease on December 20finanznachrichten.de - December 12 at 11:44 PMBioArctic AB (publ) (BIOA-B.ST)finance.yahoo.com - December 8 at 9:43 AMBioArctic AB Class B BIOA Bmorningstar.com - November 22 at 2:00 PMBioArctic: Lecanemab winner in two categories at The Scrip Awards 2023finanznachrichten.de - November 20 at 8:55 AMLecanemab winner in two categories at The Scrip Awards 2023finance.yahoo.com - November 20 at 8:55 AMBioArctic: Update relating to LEQEMBI® from Eisai's investor presentation of their quarterly report published todayfinanznachrichten.de - November 7 at 9:01 AMLEQEMBI® Q3 2023 sales published - 0.4 billion yen recorded in the periodfinance.yahoo.com - November 7 at 4:01 AMUpdate relating to LEQEMBI® from Eisai's investor presentation of their quarterly report published todayfinance.yahoo.com - November 7 at 4:01 AMBioArctic and Eisai announce new positive data for SC versus IV Leqembi studymsn.com - October 27 at 8:36 PMBioArctic: New data from LEQEMBI® (lecanemab-irmb) phase 3 Clarity AD study and subcutaneous formulation presented at CTADfinanznachrichten.de - October 26 at 1:31 AMNew data from LEQEMBI® (lecanemab-irmb) phase 3 Clarity AD study and subcutaneous formulation presented at CTADfinance.yahoo.com - October 26 at 1:31 AMLecanemab named one of the world's best inventions in 2023 by TIMEfinance.yahoo.com - October 24 at 12:51 PMNew data from LEQEMBI® (lecanemab-irmb) phase 3 Clarity AD study and subcutaneous formulation to be presented at CTADfinance.yahoo.com - October 16 at 8:04 AM'LEQEMBI® Intravenous Infusion' approved for the treatment of Alzheimer's disease in Japanfinance.yahoo.com - September 25 at 10:35 AMShearing dream for former Hawke’s Bay rugby hopefulmsn.com - September 20 at 8:52 AMJapan grants patent for BioArctic’s Parkinson’s disease antibodymsn.com - August 24 at 10:20 AMBioArctic receives patent in Japan for new antibodies targeting Parkinson's diseasebenzinga.com - August 23 at 7:12 AMInjured girl’s family ‘outraged’ at minor charges in fatal Florida Keys boat crash probemsn.com - August 11 at 8:02 PMBritish Bankers Association (BBA) Definitioninvestopedia.com - July 21 at 1:30 PMLatest analysis of lecanemab's effect on biomarkers as well as new data on subcutaneous dosing presented at the AAIC 2023 Alzheimer conferencefinance.yahoo.com - July 20 at 12:41 AMBioArctic: Latest data on lecanemab to be presented at Alzheimer's Association International Conference (AAIC) 2023finanznachrichten.de - July 12 at 10:32 AMLatest data on lecanemab to be presented at Alzheimer's Association International Conference (AAIC) 2023finance.yahoo.com - July 11 at 11:17 PMBioArctic: FDA grants traditional approval for LEQEMBI® (lecanemab-irmb) for the treatment of Alzheimer's diseasefinanznachrichten.de - July 7 at 1:29 AMFDA Advisory Committee votes unanimously to confirm clinical benefit of LEQEMBI® (lecanemab-irmb) for the treatment of early Alzheimer's diseasefinance.yahoo.com - June 10 at 9:49 AMBioArctic: Marketing Authorization Application for lecanemab as treatment for early Alzheimer's disease filed in South Koreafinanznachrichten.de - June 8 at 12:35 AMMarketing Authorization Application for lecanemab as treatment for early Alzheimer's disease filed in South Koreafinance.yahoo.com - June 8 at 12:35 AM Get (BIOA) News Delivered to You Automatically Sign up to receive the latest news and ratings for BIOA and its competitors with MarketBeat's FREE daily newsletter. Email Address Move Your Money Before May 1 (Ad)Did you know that the IRS has allegedly been using AI to spy on the bank accounts of American citizens? Click here to get the full story before May 1. BIOA Media Mentions By Week BIOA Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BIOA News Sentiment▼0.000.42▲Average News Sentiment BIOA News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BIOA Articles This Week▼21▲BIOA Articles Average Week Get (BIOA) News Delivered to You Automatically Sign up to receive the latest news and ratings for BIOA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:BIOA) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersThese AI trades triggered this morning (545% return)Prosper Trading AcademyConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithFed launches fourth dollar overhaulStansberry ResearchJeff Bezos Just Humiliated Elon MuskInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding (BIOA) Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
